Rio Nakamura
About
Rio Nakamura is a scholar working on Molecular Medicine, Pharmacology and Molecular Biology.
According to data from OpenAlex, Rio Nakamura has authored 29 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Medicine, 21 papers in Pharmacology and 7 papers in Molecular Biology. Recurrent topics in Rio Nakamura's work include Antibiotic Resistance in Bacteria (23 papers), Antibiotics Pharmacokinetics and Efficacy (20 papers) and Infections and bacterial resistance (6 papers). Rio Nakamura is often cited by papers focused on Antibiotic Resistance in Bacteria (23 papers), Antibiotics Pharmacokinetics and Efficacy (20 papers) and Infections and bacterial resistance (6 papers). Rio Nakamura collaborates with scholars based in Japan and United States. Rio Nakamura's co-authors include Yoshinori Yamano, Masakatsu Tsuji, Takafumi Sato, Akinobu Ito, Shuhei Matsumoto, Toru Nishikawa, Naoki Kohira, Hidenori Yoshizawa, Tsukasa Ito-Horiyama and Stephen Rittenhouse and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy and European Journal of Medicinal Chemistry.
In The Last Decade
Rio Nakamura
29 papers receiving 1.5k citations
Peers
Rio Nakamura
Takafumi Sato Japan
Boudewijn L. M. de Jonge United States
Alyssa Golden Canada
Andrew Denisuik Canada
Xavier Mulet Spain
Sofia K. Kasiakou Greece
Marisa Winkler United States
Naoki Kohira Japan
Neang S. Ly United States
Melissa D. Barnes United States
Citations per year, relative to Rio Nakamura Rio Nakamura (= 1×)
peers
Takafumi Sato
Countries citing papers authored by Rio Nakamura
Since
Specialization
Citations
This map shows the geographic impact of Rio Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rio Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rio Nakamura more than expected).
Fields of papers citing papers by Rio Nakamura
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Rio Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rio Nakamura. The network helps show where Rio Nakamura may publish in the future.
Co-authorship network of co-authors of Rio Nakamura
This figure shows the co-authorship network connecting the top 25 collaborators of Rio Nakamura. A scholar is included among the top collaborators of Rio Nakamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rio Nakamura. Rio Nakamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Takemura, Miki, Rio Nakamura, Ryuichiro Nakai, et al.. (2023). In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. Antimicrobial Agents and Chemotherapy. 67(12). e0034623–e0034623.
2.
Kusano, Hiroki, Toshiaki Aoki, Takuya Oguma, et al.. (2022). Discovery of a Tricyclic β-Lactam as a Potent Antimicrobial Agent against Carbapenem-Resistant Enterobacterales, Including Strains with Reduced Membrane Permeability and Four-Amino Acid Insertion into Penicillin-Binding Protein 3: Structure–Activity-Relationships and In Vitro and In Vivo Activities. ACS Infectious Diseases. 8(3). 400–410.
3.
Nakamura, Rio, et al.. (2021). In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia. Antimicrobial Agents and Chemotherapy. 65(4).
4.
Nakamura, Rio, et al.. (2021). 1058. In Vitro and In Vivo Antibacterial Activity of Cefiderocol against Burkholderia spp. Open Forum Infectious Diseases. 8(Supplement_1). S621–S621.
5.
Nakai, Ryuichiro, Rio Nakamura, Meredith Hackel, et al.. (2021). 1066. In Vitro and in Vivo Antimicrobial Activity of Cefiderocol and Comparators against Achromobacter spp. Open Forum Infectious Diseases. 8(Supplement_1). S625–S626.
6.
Yamano, Yoshinori, Rio Nakamura, Miki Takemura, & Roger Echols. (2020). 1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies. Open Forum Infectious Diseases. 7(Supplement_1). S730–S730.
7.
Yamano, Yoshinori, et al.. (2020). 1626. Synergistic Effect of Cefiderocol with Other Antibiotics Against PER-Producing Acinetobacter baumannii Isolates from the Multinational SIDERO-WT Studies. Open Forum Infectious Diseases. 7(Supplement_1). S805–S805.
8.
Nakamura, Rio, Meredith Hackel, Roger Echols, et al.. (2020). 164. in Vitro Antibacterial Activity of Cefiderocol Against Non-fermenter Clinical Strains Collected in North America and Europe from Multinational Surveillance Studies SIDERO-WT-2014–2018. Open Forum Infectious Diseases. 7(Supplement_1). S211–S212.
9.
Nakamura, Rio, Tsukasa Ito-Horiyama, Miki Takemura, et al.. (2019). In Vivo Pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models. Antimicrobial Agents and Chemotherapy. 63(9).
10.
Aoki, Toshiaki, Hidenori Yoshizawa, Kenji Yamawaki, et al.. (2018). Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship. European Journal of Medicinal Chemistry. 155. 847–868.
11.
Matsumoto, Shuhei, et al.. (2017). In Vivo Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Murine Urinary Tract Infection Models. Open Forum Infectious Diseases. 4(suppl_1). S472–S472.
12.
Matsumoto, Shuhei, Jennifer L. Hoover, Rio Nakamura, et al.. (2017). Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics. Antimicrobial Agents and Chemotherapy. 61(9).
13.
Ito, Akinobu, Takafumi Sato, Miki Takemura, et al.. (2017). In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrobial Agents and Chemotherapy. 62(1).
14.
Yamano, Yoshinori, Rio Nakamura, Takafumi Sato, Masakatsu Tsuji, & Roger Echols. (2017). Good Correlation of Cefiderocol Between In Vivo Efficacy Murine Thigh/Lung Infection Models and MIC Determined in Iron-Depleted Conditions. Open Forum Infectious Diseases. 4(suppl_1). S476–S477.
15.
Ito, Akinobu, Toru Nishikawa, Shuhei Matsumoto, et al.. (2016). Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 60(12). 7396–7401.
16.
Yamawaki, Kenji, Shuji Yonezawa, Yoshinori Yamano, et al.. (2016). Novel broad-spectrum and long-acting parenteral cephalosporins having an acyl cyanamide moiety at the C-3 terminal: Synthesis and structure-activity relationships. European Journal of Medicinal Chemistry. 124. 698–712.
17.
Ito, Akinobu, Naoki Kohira, Samuel K. Bouchillon, et al.. (2015). In vitroantimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 71(3). 670–677.
18.
Tsuji, Masakatsu, Takahiro Yamaguchi, Rio Nakamura, et al.. (2015). S-649266, A Novel Siderophore Cephalosporin: In Vitro Activity Against Gram-Negative Bacteria Isolated in Japan Including Carbapenem-Resistant Strains. Open Forum Infectious Diseases. 2(suppl_1). 778–778.
19.
Tsuji, Masakatsu, Tsukasa Horiyama, Rio Nakamura, et al.. (2014). 248S-649266, a Novel Siderophore Cephalosporin: Efficacy against Klebsiella pneumoniae producing NDM-1 or KPC in rat lung infection model with recreated humanized exposure profile of 2 gram dose with 1 hour and 3 hours infusion. Open Forum Infectious Diseases. 1(suppl_1). S106–S107.
20.
Ito, Akinobu, et al.. (2014). Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.. PubMed. 67(2). 109–22.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Takafumi Sato Breakdown of academic impact, for papers by Boudewijn L. M. de Jonge Breakdown of academic impact, for papers by Alyssa Golden Breakdown of academic impact, for papers by Andrew Denisuik Breakdown of academic impact, for papers by Xavier Mulet Breakdown of academic impact, for papers by Sofia K. Kasiakou Breakdown of academic impact, for papers by Marisa Winkler Breakdown of academic impact, for papers by Naoki Kohira Breakdown of academic impact, for papers by Neang S. Ly Breakdown of academic impact, for papers by Melissa D. Barnes